Pharmafile Logo
Pharmafocus logo
Advanced Search

Research and Development

Showing 15 posts of 9573 posts found.

merckwindow_web

Bittersweet Phase 3 Keytruda data hits one of two goals in extensive stage small cell lung cancer

January 7, 2020 Manufacturing and Production, Research and Development MSD, keytruda

MSD has lifted the curtain on new Phase 3 data on the efficacy of its blockbuster immunotherapy Keytruda, in combination …
News
stock-incyte-01-shutter

Incyte’s drug stumbles at Phase 3 in treatment-naive acute graft-versus-host disease

January 6, 2020 Research and Development, Sales and Marketing Incyte, pharma, trial failure

Drugmaker Incyte has made it known that its selective JAK1 inhibitor therapy itacitinib fell short at Phase 3 in the …
News
merck__co

FDA advisory panel back Merck & Co.’s Keytruda treatment for bladder cancer

December 18, 2019 Research and Development FDA, Merck, Merck and Co, NHS, NICE, keytruda

An FDA advisory committee voted 9 to 4 in favour of recommending Merk and Co’s Keytruda (pembrolizumab) for treatment in …
News
1024px-nhs-logo

NHS Scotland gives green light to funding haemophilia A drug Hemlibra

December 18, 2019 Research and Development NHS, haemophilia, haemophilia B, haemophilia a, nhs scotland

NHS Scotland has commissioned Hemlibra (emicizumab), by Chungai Pharma UK Ltd and Roche Products Ltd, to treat people with congenital …
News
47699364212_411beea163_b

Eli Lilly CEO says Elizabeth Warren’s claims they failed on cheaper insulin is ‘nonsense’

December 18, 2019 Research and Development Bernie Sanders, Eli Lilly, Elizabeth Warren, US Pharma, US Presidential Election, insulin

David Ricks, the CEO of Eli Lilly, has said that Presidential candidate Senator Elizabeth Warren’s claims his company failed on …
News
5204602349_c87b204860_b

FDA advisory committee approves the use of Lynparza in pancreatic cancer

December 18, 2019 Research and Development AstraZeneca, Cancer, Merck, Pancreatic cancer, lynparza

The FDA’s Oncologic Drugs Advisory Committee (ODAC) has recommended the approval of AstraZeneca and Merck’s Lynparza (olaparib) to treat pancreatic …
News
roche

Roche’s Tecentriq combo boosts progression-free survival in previously untreated BRAF V600 mutation-positive advanced melanoma

December 16, 2019 Manufacturing and Production, Research and Development, Sales and Marketing Roche, melanoma, pharma, tecentriq

Roche has lifted the curtain on new Phase 3 data for its immunotherapy Tecentriq (atezolizumab), confirming that the therapy, when …
News
insider_interview_andrew_roach

A new weapon against Parkinson’s-related psychosis

December 16, 2019 Business Services, Manufacturing and Production, Medical Communications, Research and Development, Sales and Marketing Parkinson's disease, cannabidiol, cannabis, feature, pharma

Dr Arthur Roach, Director of Research at the charity Parkinson’s UK, discusses new trials on cannabidiol in the treatment of …
Feature
shutterstock_gonnorrhea

Transgene ceases development of failed advanced non-squamous non-small cell lung cancer immunotherapy candidate

December 16, 2019 Research and Development, Sales and Marketing Cancer, Transgene, lung cancer, pharma

Cancer immunotherapeutics firm Transgene has confirmed that it is to terminate further development of its TG4010 candidate in the first-line …
News

Novartis pulls fevipiprant development in asthma following trial failure

December 16, 2019 Research and Development, Sales and Marketing Fevipiprant, Novartis, asthma, pharma, trial failure

Novartis has made it known that its DP2 receptor antagonist fevipiprant failed at Phase 3 to show clinically relevant levels …
News

Biogen terminates gosuranemab in progressive surpanuclear palsy following Phase 2 failure

December 16, 2019 Research and Development, Sales and Marketing Biogen, pharma, trial failure

Biogen has revealed its intention to shut down further development of gosuranemab after results of a Phase 2 study showed …
News
4420456374_64a3d7e6aa

Top Ten most popular articles on Pharmafile.com this week

December 13, 2019 Business Services, Manufacturing and Production, Medical Communications, Research and Development, Sales and Marketing pharma, top ten

As the UK reels from the news that Boris Johnson and the Conservative Party have stormed the general election and …
News
roche

Roche’s subcutaneous Perjeta/Herceptin combo proves non-inferior to IV formulation in HER2-positive early breast cancer

December 12, 2019 Research and Development Cancer, Herceptin, Perjeta, Roche, breast cancer, pharma

New Phase 3 data from Roche has shown that its subcutaneously-delivered formulation of Perjeta (pertuzumab) and Herceptin (trastuzumab), in combination …
News
shutterstock_512649

New NAFTA terms put hold on Canadian drug prices

December 11, 2019 Research and Development, Sales and Marketing Canada, NAFTA, US, pharma

NAFTA members have agreed to remove a provision that would have increased protections on biologics drugs. This means Canada, despite …
News
6127243966_e9189f1099_b

Multiple sclerosis market to be worth $32.9bn in 2028

December 11, 2019 Research and Development Big Pharma, MS, MS treatement, multiple sclerosis, pharma

The multiple sclerosis (MS) market is expected to see a growth in sales, and increase from $19.8 billion in 2018 …
News
The Gateway to Local Adoption Series

Latest content

STADA and Bio-Thera’s Gotenfia receives positive CHMP opinion for autoimmune diseases

December 18, 2025

Norgine enters exclusive licensing agreement with Vir Biotechnology

December 18, 2025

Incyclix appoints Kimberly Blackwell to Board of Directors

December 17, 2025

Hansa Biopharma appoints Max Sakajja as Vice President, General Manager Europe and International

December 17, 2025

GSK’s Exdensur receives MHRA approval for asthma and rhinosinusitis

December 16, 2025